On the Electrical Resistance Relaxation of 3D-Anisotropic Carbon-Fiber-Filled Polymer Composites Subjected to External Electric Fields.

Flexible composites as sensors are applied under a small voltage, but the effect of the external electrical field on the resistance is always ignored and unexplored by current research. Herein, we investigate the electrical resistance relaxation of anisotropic composites when they are subjected to an external electric field. The anisotropic composites were 3D-printed based on carbon-fiber-filled silicon rubber. Constant DC voltages were applied to the composites, and the output electrical current increased with time, namely the electrical resistance relax with time. The deflection and migration of carbon fibers are dominantly responsible for the resistance relaxation, and the angle's evolution of a carbon fiber, under the application and removal of the electrical field, was well observed. The other factor hindering the resistance relaxation is the increased temperature originating from the Joule heating effect. This work provides a new understanding in the working duration and the static characteristics of flexible composites.

CABYR is a novel cancer-testis antigen in lung cancer.

PURPOSE: Cancer-testis (CT) antigens are often expressed in a proportion of tumors of various types. Their restricted normal tissue expression and immunogenicity make them potential targets for immunotherapy. CABYR is a calcium-binding tyrosine phosphorylation-regulated fibrous sheath protein initially reported to be testis specific and subsequently shown to be present in brain tumors. This study was to determine whether CABYR is a novel CT antigen in lung cancer. EXPERIMENTAL DESIGN: mRNA expression of CABYR-a/b (combination of CABYR-a and CABYR-b) and CABYR-c was examined in 36 lung cancer specimens, 14 cancer cell lines, and 1 normal cell line by conventional and real-time reverse transcription-PCR. Protein expression of CABYR was analyzed in 50 lung cancer tissues by immunohistochemistry. Antibodies specific to CABYR were analyzed in sera from 174 lung cancer patients and 60 healthy donors by ELISA and Western blot. RESULTS: mRNA expression of CABYR-a/b and CABYR-c was observed, respectively, in 13 and 15 of 36 lung cancer tissues as well as in 3 and 5 of 14 cancer cell lines, whereas neither of them was observed in adjacent noncancerous tissues or the normal cell line. Protein expression of CABYR-a/b and CABYR-c was observed, respectively, in 20 and 19 of 50 lung cancer tissues. IgG antibodies specific to CABYR-a/b and CABYR-c were detected, respectively, in 11% and 9% of sera from lung cancer patients but not from the 60 healthy donors. CONCLUSION: CABYR is a novel CT antigen in lung cancer and may be a promising target for immunotherapy for lung cancer patients.